Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Safety and efficacy of ritonavir and saquinavir in combination with zidovudine and lamivudine.

Clinical pharmacology and therapeutics - 1 Jun 1999

Michelet C, Bellissant E, Ruffault A, Arvieux C, Delfraissy J F, Raffi F, Bazin C, Renard I, Sébille V, Chauvin J P, Dohin E, Cartier F

Abstract excerpt

BACKGROUND: Ritonavir is a potent inhibitor of cytochrome P4503A4 that strongly increases saquinavir bioavailability. In this study we assessed the safety and antiretroviral efficacy of the combination of these two compounds in patients pretreated and receiving continued treatment with zidovudine and lamivudine who were protease inhibitor naive and who had a CD4 cell counts below 200/mm3. METHODS: In this 48-week...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acquired Immunodeficiency Syndrome
Share to CD4 Lymphocyte Count

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Administration Schedule

Share to HIV Protease Inhibitors

Share to Lamivudine

Share to Ritonavir

Share to Saquinavir

Share to Zidovudine

Source

Identifiers

PMID: 10391672
DOI: 10.1016/S0009-9236(99)90088-7

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Safety and efficacy of ritonavir and saquinavir in combination with zidovudine and lamivudine.PMID 10391672Read ↗

Toxicity, efficacy, plasma drug concentrations and protease mutations in patients with advanced HIV infection treated with ritonavir plus saquinavir. Swiss HIV Cohort Study.Semantic proximity Read ↗

Efficacy of a five-drug combination including ritonavir, saquinavir and efavirenz in patients who failed on a conventional triple-drug regimen: phenotypic resistance to protease inhibitors predicts outcome of therapy.Semantic proximity Read ↗

Pharmacokinetics and resistance mutations affect virologic response to ritonavir/saquinavir-containing regimens.Semantic proximity Read ↗

The rabbit study: ritonavir and saquinavir in combination in saquinavir-experienced and previously untreated patients.Semantic proximity Read ↗

Efficacy, tolerance, and pharmacokinetics of the combination of stavudine, nevirapine, nelfinavir, and saquinavir as salvage regimen after ritonavir or indinavir failure.Semantic proximity Read ↗

Comparison of the efficacy, safety and predictive value of HIV genotyping using distinct ritonavir-boosted protease inhibitors.Semantic proximity Read ↗

Performance of six different ritonavir-boosted protease inhibitor-based regimens in heavily antiretroviral-experienced HIV-infected patients.Semantic proximity Read ↗

Rational approaches to resistance: using saquinavir.Semantic proximity Read ↗

Drug monitoring and viral response to lopinavir/ritonavir or saquinavir/ritonavir containing regimens in individuals infected with the human immunodeficiency virus type 1.Semantic proximity Read ↗

Ritonavir, saquinavir combination--& warning.Semantic proximity Read ↗

The cumulative occurrence of resistance mutations in the HIV-1 protease gene is associated with failure of salvage therapy with ritonavir and saquinavir in protease inhibitor-experienced patients.Semantic proximity Read ↗

Salvage therapy with amprenavir and ritonavir: prospective study in 17 heavily pretreated patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.